Skip to main content

Aroa Soriano Fernández

Institutions of which they are part

Main researcher
Childhood Cancer and Blood Disorders
Vall Hebron Institut de Recerca

Aroa Soriano Fernández

Institutions of which they are part

Main researcher
Childhood Cancer and Blood Disorders
Vall Hebron Institut de Recerca

Projects

JARC: Joint Action on Rare Cancers Grant Agreement: 724161 VHIR involved in WP9 Task 2 : Objective Use of relevant paediatric preclinical models (patients derived xenografts, genetically modified models, other preclinical model) for experimental

IP: Miguel Segura Ginard
Collaborators: Soledad Gallego Melcón, Aroa Soriano Fernández, Josep Roma Castanyer
Funding agency: Ex. Agency for Health Consumers (EAHC)-CHAFEA
Funding: 6959.28
Reference: JARC_3HP-CHAFEA2015
Duration: 01/10/2016 - 30/09/2019

Investigació translacional en càncer infantil (GRE)

IP: Josep Sánchez de Toledo Codina
Collaborators: Soledad Gallego Melcón, Aroa Soriano Fernández, Maria Cristina Díaz de Heredia Rubio, Miguel Segura Ginard, Anna Llort Sales, Raquel Hladun Alvaro, Laura Alonso Garcia, Josep Roma Castanyer
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 30000
Reference: 2014 SGR 660
Duration: 01/01/2014 - 31/12/2016

Nanoterapia basada en microRNAs: nuevo tratamiento para tumores pediátricos del sistema nervioso

IP: Miguel Segura Ginard
Collaborators: Luís Gros Subias, Aroa Soriano Fernández, Josep Sánchez de Toledo Codina, Constantino Sábado Álvarez
Funding agency: Instituto de Salud Carlos III
Funding: 116765
Reference: PI14/00561
Duration: 01/01/2015 - 31/12/2017

TERAPIA PERSONALIZADA CONTRA ERK5 EN NEUROBLASTOMA

IP: Aroa Soriano Fernández
Collaborators: Soledad Gallego Melcón, Miguel Segura Ginard
Funding agency: Asociación Española Contra el Cáncer
Funding: 20000
Reference: 2014/AECC-JB/SORIANO
Duration: 31/01/2015 - 31/01/2017

Related news

Vall d’Hebron participates as a reference centre in Spain for early-phase clinical trials and coordinates the national ReALLNet network, promoting research into relapsed acute lymphoblastic leukemia.

The PHOENIX project, involving 13 European institutions, will evaluate for the first time in paediatric patients the drug ibrilatazar from AbilityPharma in a phase I/II clinical trial.

The European initiative Hope4Kids will strengthen and harmonise paediatric palliative care across Europe, with the aim of ensuring comprehensive, high-quality care for all children living with life-threatening or life-limiting conditions.

Related professionals

Montserrat Lolo Carrete

Montserrat Lolo Carrete

Research assistant
Multidisciplinary Nursing Research Group
Read more
Galo David Granados Rosales

Galo David Granados Rosales

Predoctoral researcher
Pneumology
Read more
Carlos Lozano Galende

Carlos Lozano Galende

Gestió i Administració
Software Engineering Unit
Digital Transformation Directorate
Read more
Mamadou Fall Sarr

Mamadou Fall Sarr

Postdoctoral researcher
Infectious Diseases
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.